TITLE

COMMENTARY: Long-term use of combination DMARDs did not sustain disease remissions, but delayed joint damage in early rheumatoid arthritis

AUTHOR(S)
Sander, Oliver
PUB. DATE
January 2005
SOURCE
ACP Journal Club;Jan/Feb2005, Vol. 142 Issue 1, p9
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that long-term use of combination disease-modifying antirheumatic drugs (DMARDs) did not sustain disease remissions, but delayed joint damage in early rheumatoid arthritis. In 1990s, the benefit of combination therapy with methotrexate, sulfasalazine and antimalarials was seen. Side effects of these combinations have remained problematic, however. Early, aggressive therapy can improve function and reduce inflammation, radiology damage, loss of function and mortality.
ACCESSION #
15851774

 

Related Articles

  • Romatoid Artrit ve HastaliÄŸi Modifiye Edici Antiromatizmal ilaçlar. Güzel, Rengin // Turkish Journal of Physical Medicine & Rehabilitation / Turkiye ;mai2008 Supplement, Vol. 54 Issue 1, p25 

    It has now been well established that in Rheumatoid Arthritis early treatment with disease modifying antirheumatic drugs (DMARDs) should be initiated to control the inflammatory activity, structural damage and function. Toxicity of the drugs should be monitored carefully. In cases with...

  • Prevalence of and predictive factors for sustained diseasemodifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.  // International Journal of Advances in Rheumatology;2009, Vol. 7 Issue 4, p126 

    This study of two cohorts of rheumatoid arthritis (RA) patients revealed that up to 15% of those who were treated with conventional therapy (disease-modifying anti-rheumatic drugs [DMARDs] or nonsteroidal antiinflammatory drugs) had sustained DMARD-free remission. Furthermore, this remission...

  • Expression of multidrug resistance-1 protein correlates with disease activity rather than the refractoriness to methotrexate therapy in rheumatoid arthritis. Agarwal, V.; Mittal, S. K.; Misra, R. // Clinical Rheumatology;Apr2009, Vol. 28 Issue 4, p427 

    Disease-modifying antirheumatic drugs (DMARDs) improve the disability and slow the progression of the joint damage in rheumatoid arthritis (RA). However, a large proportion of patients experience inefficacy by the end of 2 years. This loss of efficacy may be due to expression of multidrug...

  • Long-term use of combination DMARDs did not sustain disease remissions, but delayed joint damage in early rheumatoid arthritis. M, Korpela // ACP Journal Club;Jan/Feb2005, Vol. 142 Issue 1, p9 

    The article reports that long-term use of combination disease-modifying antirheumatic drugs (DMARDs) did not sustain disease remissions, but delayed joint damage in early rheumatoid arthritis. Remission extent of radiology damage in the joints of the hands and feet, adverse events and...

  • Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis? Goodemote, Patricia; Jamieson, Barbara // Journal of Family Practice;Nov2007, Vol. 56 Issue 11, p933 

    The article presents a clinical inquiry about the effectiveness of disease-modifying antirheumatic agents (DMARDs) for treating rheumatologic diseases in addition to rheumatoid arthritis (RH). According to the authors, the use of DMARDs has become the standard of care, however, its use in...

  • Management of joint disorders with special attention to Rheumatoid arthritis and Chrysotherapy. Rout, Susanta Kumar; Dutta, Saptarshi; Sengupta, Mukul; Das, Srimanta Kumar // Journal of Pharmacy Research;May2010, Vol. 3 Issue 5, p1007 

    Management of Joint disorders and rheumatologic diseases has come a long way beyond prescribing NSAIDs, DMARDS and steroids. The non steroidal anti inflammatory drugs are among the most widely prescribed and used drugs in the Hospital or community Health centre for rheumatologic as well as non...

  • Celecoxib for Rheumatoid Arthritis. Megeff, Carla E.; Strayer, Scott M. // Journal of Family Practice;Feb2000, Vol. 49 Issue 2, p108 

    This article discusses a study on the anti-inflammatory and upper gastrointestinal effects of celecoxib on rheumatoid arthritis. The study included adult patients with a mean age of 54 years, who met the American College of Rheumatology diagnostic criteria for rheumatoid arthritis for 3 months...

  • Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis.  // BMC Pediatrics;2012, Vol. 12 Issue 1, p29 

    The article focuses on a systematic review that compares the effectiveness and safety of disease-modifying antirheumatic drugs (DMARDs) and conventional therapy in the treatment of juvenile idiopathic arthritis (JIA). It states that the reports of human studies on the treatment of JIA, juvenile...

  • News from EULAR.  // PharmacoEconomics & Outcomes News;7/25/2009, Issue 583, p7 

    The article discusses studies presented at the 10th Annual Congress of the European League Against Rheumatisim (EULAR). A study evaluated the costs and benefits of etanercept plus nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with severe ankylosing spondylitis (AS). Research found...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics